NEW YORK – Proteomics International (PIL) said it has ended its licensing agreement with Sonic Healthcare USA for the use and commercialization in the US of its Promarker D test for diabetic kidney disease.
According to PIL, termination of the exclusive licensing agreement was due to a failure to meet certain milestones and performance indicators required under the agreement for commercialization of the test to occur. Details of those milestones and indicators were not disclosed.
The two companies entered into the licensing agreement in May of 2023, and the termination took effect on Sept. 10.
Having ended the agreement, Nedlands, Australia-based PIL is free to license the Promarker D test to other parties in the US. The company said that it is in discussions with various service providers about offering the test in the US and also plans to offer it directly to consumers. It added that the test has been established in a third-party CLIA lab in preparation for a US launch.